SpringWorks Therapeutics SWTX 深 沪
已收盘 07-01 16:00:00 美东时间
46.99
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 46.99
- 总市值 35.41亿
- 52周最高 62.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 28.21
- 委 比 0.00%
- 总股本 7534.90万
- 历史最高 96.48
- 量 比 0
- 振 幅 0.00%
- 历史最低 13.60
- 每 手 1
- 风险率 6.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多默克换帅，新CEO将上任
近日，默克官方发布了一则任命新CEO的公告。公告中称：任命毕康明(Kai Beckmann)为默克集团候任执行董事会主席兼首席执行官,他将于2026年5月1日正...
09-26 17:15
默克确定新任CEO
（来源：求实药社） 2025年9月25日，默克集团（Merck KGaA）正式宣布，现任电子业务CEO Kai Beckmann将自2026年5月1日起接任...
09-26 12:02
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
SpringWorks Therapeutics announced that the European Commission has granted marketing authorization for OGSIVEO® (nirogacestat) as the first and only therapy approved in the EU for the treatment of adults with progressing desmoid tumors requiring systemic treatment. The approval is based on the Phase 3 DeFi trial, which demonstrated significant improvements in progression-free survival (PFS), objective response rate (ORR), and patient-reported ou...
08-18 13:10
传默克集团拟发行40亿美元债券 为收购SpringWorks提供资金
据知情人士透露，德国默克集团(Merck KGaA)计划发行约40亿美元的美国投资级债券，为其对SpringWorks Therapeutics的收购提供资金。
08-12 07:57
Merck KGaA gets EU nod for Ezmekly
Merck KGaA (NYSE:MRK) said that the European Commission approved Ezmekly for treating symptomatic, inoperable plexiform neurofibromas in patients with neurofibromatosis type 1 who are 2 years old and ...
07-19 01:02
SpringWorks Therapeutics Receives EC Conditional Marketing Approval For EZMEKLY In Treating NF1-PN Across Pediatric And Adult Patients
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted conditional marketing authorization for EZMEKLY® (mirdametinib) for
07-19 00:14
Madrigal gains after Rezdiffra patent win
Madrigal Pharmaceuticals (NASDAQ:MDGL) traded higher in the premarket on Wednesday after the company announced a patent win related to its lead asset, Rezdiffra, approved by the FDA in 2024 for a live...
07-16 20:54
California Rep. Gilbert Ray Cisneros Sold Over $28K Worth of SpringWorks Therapeutics Inc Ordinary Shares Stock: Here's What You Should Know
An official report on July 10, 2025 reveals Representative Gilbert Ray Cisneros...
07-11 23:00
